Roche's Divarasib Demonstrated Best-in-class Efficacy, Advancing Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
October 27, 2026
October 27, 2026
BASEL, Switzerland, Oct. 27 (TNSjou) -- Roche, a biotech company, issued the following news release:
* * *
Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
* Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III . . .
* * *
Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
* Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III . . .